Drug Topics March 1, 2024
Lauren Biscaldi, MS, Managing Editor

Pfizer’s RSV vaccine received FDA approval on May 31, 2023.

Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo remains efficacious in preventing RSV-associated lower respiratory tract disease in adults aged 60 years and older through 2 full RSV seasons, according to topline study data shared by the manufacturer.1

Data were gathered as part of the ongoing phase 3 RENIOR clinical trial (NCT05035212).

“We are encouraged by the level of protection that we observed after 2 full RSV seasons for Abrysvo,” said Annaliesa Anderson, PhD, senior vice president and chief scientific officer, vaccine research and development at Pfizer, in a press release.1 “This new data indicate that broad and durable protection against both types of RSV that cause disease…is the potential benefit...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID, Survey / Study, Trends
Related Articles:
Drugmakers prep for bird flu outbreak, despite continued low risk
Heart health differences in men and women: Tiny RNA molecules play key role, study finds
STAT+: Nobel laureates call on National Academies and biotech CEOs to speak out against Trump attacks on science
Healthcare supply chain, pharmacy costs to rise in 2025: report
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA

Share This Article